Chardan Capital analyst Keay Nakae reiterated a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report) today and set a price target of $11.00. The company’s shares closed today at $4.70.
Nakae covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Arrowhead Pharmaceuticals, and Seres Therapeutics. According to TipRanks, Nakae has an average return of -0.9% and a 36.75% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coya Therapeutics, Inc. with a $18.00 average price target, representing a 282.98% upside. In a report released today, BTIG also maintained a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $8.00 and a one-year low of $3.69. Currently, Coya Therapeutics, Inc. has an average volume of 116K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Read More on COYA:
